PROF Profound Medical Corp.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1628808 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY65.3%
TTM net income YoY17.4%
TTM EPS YoY295.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin73.9%
Operating margin-145.1%
Net margin-137.5%
FCF margin—
EBITDA margin-143.4%
Returns
ROE-87.0%
ROA-64.7%
ROIC (approx.)-157.1%
Asset turnover0.47x
Leverage & solvency
Liabilities / assets26.9%
Debt / equity0.21x
Current ratio4.54x
Interest coverage-105.79x
Cash quality & payout
Operating cash flow / net income0.97x
Accruals ratio-2.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $9.83M | $2.48M | $5.34M | $5.98M | $5.29M | $2.21M | $2.62M | $4.18M |
| Cost of revenue | $2.15M | $536,000 | $1.50M | $1.99M | $1.36M | $593,000 | $768,000 | $1.21M |
| Gross profit | $7.68M | $1.95M | $3.83M | $3.99M | $3.93M | $1.62M | $1.85M | $2.96M |
| R&D expense | $5.81M | $5.65M | $5.26M | $4.27M | $5.42M | $6.10M | $4.81M | $4.65M |
| SG&A expense | $9.70M | $7.36M | $6.59M | $7.09M | $7.43M | $9.33M | $8.21M | $6.66M |
| Operating income | -$7.82M | -$11.07M | -$8.02M | -$7.37M | -$8.91M | -$13.81M | -$11.17M | -$8.35M |
| Interest expense | $80,000 | $79,000 | $80,000 | $85,000 | $119,000 | $86,000 | $104,000 | — |
| Pretax income | -$7.73M | -$9.48M | -$7.03M | -$8.15M | -$7.86M | -$15.63M | -$10.68M | -$5.18M |
| Income tax | -$4,000 | $55,000 | $25,000 | $26,000 | $121,000 | $64,000 | $41,000 | -$238,000 |
| Net income | -$7.72M | -$9.54M | -$7.05M | -$8.18M | -$7.98M | -$15.70M | -$10.72M | -$4.95M |
| EBITDA | -$7.70M | -$10.94M | -$7.93M | -$7.31M | -$8.82M | -$13.70M | -$11.05M | -$8.19M |
| EPS (basic) | -0.21 | -0.26 | 0.19 | — | -0.26 | -0.52 | 0.36 | — |
| EPS (diluted) | -0.21 | -0.26 | 0.19 | — | -0.26 | -0.52 | 0.36 | — |
| Weighted avg. shares (diluted) | 36.56M | 36.35M | 36.30M | — | 30.10M | 30.05M | 30.04M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $33.34M | $38.27M | $50.30M | $59.72M | $24.83M | $35.20M | $46.43M | $54.91M |
| Inventory | $10.24M | $10.46M | $9.00M | $8.24M | $8.34M | $8.35M | $6.79M | $5.80M |
| Current assets | $54.83M | $58.86M | $69.53M | $76.09M | $41.52M | $48.81M | $59.91M | $69.06M |
| PP&E, net | $430,000 | $556,000 | $682,000 | $698,000 | $338,000 | $278,000 | $309,000 | $425,000 |
| Intangibles | $115,000 | $121,000 | $129,000 | $138,000 | $123,000 | $175,000 | $214,000 | $261,000 |
| Total assets | $58.15M | $62.38M | $73.46M | $77.47M | $42.30M | $49.67M | $60.86M | $70.23M |
| Current liabilities | $12.06M | $9.11M | $10.61M | $6.08M | $9.94M | $5.72M | $5.29M | $6.57M |
| Short-term debt | $4.51M | $4.51M | $4.50M | — | $4.48M | — | — | $1.74M |
| Long-term debt | $4.51M | $4.51M | $4.50M | $4.50M | $4.48M | $4.46M | $4.49M | $4.66M |
| Total debt | $9.02M | $9.01M | $9.01M | $4.50M | $8.96M | $4.46M | $4.49M | $6.40M |
| Total liabilities | $15.64M | $12.58M | $14.03M | $11.04M | $10.16M | $10.41M | $10.07M | $9.81M |
| Shareholders' equity | $42.51M | $49.81M | $59.42M | $66.43M | $32.14M | $39.26M | $50.79M | $60.42M |
| Net debt | -$24.32M | -$29.26M | -$41.29M | -$55.22M | -$15.87M | -$30.73M | -$41.95M | -$48.51M |
| Shares outstanding | 36.63M | 36.53M | 36.34M | 36.29M | 30.19M | 30.05M | 30.05M | 30.04M |
| Cash flow statement | ||||||||
| Operating cash flow | -$5.01M | -$11.34M | -$8.58M | -$6.57M | -$9.61M | -$13.74M | -$8.28M | -$5.88M |
| Financing cash flow | — | — | — | $41.43M | $0 | $0 | -$290,000 | $35.44M |
| Depreciation & amortization | $126,000 | $126,000 | $93,000 | $62,000 | $93,000 | $102,000 | $116,000 | $160,000 |
| Stock-based compensation | $257,000 | $874,000 | $1.05M | $1.38M | $1.67M | $1.45M | $989,000 | $442,000 |
Free plan shows the latest 8 periods; Pro shows all 11 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.